Predict your next investment

HEALTHCARE | Biotechnology
aviabiosystems.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$2.35M

Revenue

$0000 

About AVIA Biosystems

AVIA Biosystems is dedicated to developing and commercializing new products for the biochemical and biophysical characterization of biologics and other biomolecules. The first product to be developed by AVIA is the fluorescence-based Model 2304 Fully Automated Protein Denaturation System.

AVIA Biosystems Headquarter Location

6940 Koll Center Parkway

Pleasanton, California, 94566,

United States

925-587-9800

Latest AVIA Biosystems News

Unchained Labs lands another win in the biologics stability market! Acquires AVIA Biosystems

Jun 4, 2015

Acquires AVIA Biosystems PLEASANTON, Calif., June 4, 2015 /PRNewswire/ -- Unchained Labs upped its game in the biologics stability market today, announcing the acquisition of AVIA Biosystems, the developer of the Isothermal Chemical Denaturation (ICD) system for measuring biologic stability. This is the second acquisition for Unchained Labs this year. The ICD system makes something that wasn't possible before — the routine measurement of protein stability under denaturing conditions — totally doable. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk-away solution. The ICD system is also a perfect complement for Unchained Labs' first product, the UNit, which simultaneously measures the top two biologic stability indicators, protein unfolding and aggregation temperatures. "We are totally committed to improving biologics characterization tools and the ICD is a great new tool that can actually help predict future drug stability," said Tim Harkness, Founder and CEO of Unchained Labs. "The ICD and the UNit are a perfect pairing and really help establish us as the experts in protein stability. We have done a lot and done it quickly at Unchained Labs, but we are unwavering in our pledge to acquire any product or business that can make a real difference for biologics researchers. " "I'm really looking forward to joining forces with the Unchained Labs team," said Dr. Rick Brown, Co-founder and President of AVIA Biosystems. "Together, our products will give drug discovery researchers the power to characterize and understand their biologics better than they ever could before. " Unchained also announced the addition of $6 million to its Series A Financing, bringing the total Series A round to $31M. The original syndicate partners, Novo Ventures, Canaan Partners and TPG Biotech all participated in the financing. About Unchained Labs Unchained Labs is committed to building the first cool biologics tools company. One that matters. One without old school rules. One with products that'll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com . Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AVIA Biosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AVIA Biosystems is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

AVIA Biosystems Patents

AVIA Biosystems has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2015

3/28/2017

Monoclonal antibodies, Molecular biology, Proteins, Biotechnology, Pharmaceutical industry

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/12/2015

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/28/2017

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoclonal antibodies, Molecular biology, Proteins, Biotechnology, Pharmaceutical industry

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.